Catch the knife !I found this stock interesting for in-day trading on Monday, Jan 24, if we will go green in SPX, it might go up to $4.00 at least. Also there is a big support right where the price seating now.
buy: $3.5-3.7
sell: 4.0-4.5
−0.93USD
−41.44 MUSD
488.00 KUSD
41.07 M
About Cardiff Oncology, Inc.
Sector
Industry
CEO
Mark Erlander
Website
Headquarters
San Diego
Employees (FY)
32
Founded
1999
ISIN
US14147L1089
FIGI
BBG000PXLKM7
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.
CRDF Daily chart Cup n handle formation. Waiting for a break above the cup for a buy . Pt 25 and sl 7
Cardiff Oncology Inc 🧙Cardiff Oncology Inc is a clinical-stage, biotechnology company, developing treatment options for cancer patients in indications with the greatest medical need, including KRAS-mutated metastatic colorectal cancer, pancreatic cancer, metastatic castrate-resistant prostate cancer and leukemias.
If yo
$CRDF - Bullish$CRDF
Looking Bullish
In: 9.3 - 9.4
Target Price: 10.1
Stop Loss: 9:00
Risk rate: 2/1
CRDF Buy In Point is Here!CRDF is at a double support currently. Could be a really good buy in point here. Don't be afraid to buy in small portions. 1st target is $15 to see if we get past that natural resistance.
Options could be a possible way to go as well.
Also, don't forget Cardiff is speaking at a virtual presentati
Long | CRDF | Swing TradeNASDAQ:CRDF
Possible Scenario: LONG
Evidence: Price Action, Reversal Candlestick, Unusual option activities for Feb 19 at 20$
TP1: 15$, TP2: 19$
Mental Stop loss: 10.80$, risk reward ratio is 5 to 1
This is my idea and could be wrong 100%.
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where CRDF is featured.
Frequently Asked Questions
The current price of CRDF is 4.50 USD — it has decreased by 1.96% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Cardiff Oncology, Inc. stocks are traded under the ticker CRDF.
Cardiff Oncology, Inc. is going to release the next earnings report on May 2, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for Cardiff Oncology, Inc. has a max estimate of 14.00 USD and a min estimate of 7.00 USD.
CRDF earnings for the last quarter are −0.22 USD whereas the estimation was −0.28 USD which accounts for 22.54% surprise. Estimated earnings for the next quarter are −0.27 USD. See more details about Cardiff Oncology, Inc. earnings.
Cardiff Oncology, Inc. revenue for the last quarter amounts to 141.00 K USD despite the estimated figure of 50.00 K USD. In the next quarter revenue is expected to reach 50.00 K USD.
Yes, you can track Cardiff Oncology, Inc. financials in yearly and quarterly reports right on TradingView.
Like other stocks, CRDF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Cardiff Oncology, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 18, 2024, the company has 32.00 employees. See our rating of the largest employees — is Cardiff Oncology, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Cardiff Oncology, Inc. EBITDA is −45.01 M USD, and current EBITDA margin is −9.22 K%. See more stats in Cardiff Oncology, Inc. financial statements.